AbbVie to discount HCV drugs for state HIV programs

State HIV programs will be able to offer AIDS patients a significant discount on AbbVie's HCV combo drug, Viekira Pak, Bloomberg reported last Friday, thanks to a deal brokered by a special group.


The group that negotiated the price cut, called the ADAP Crisis Task Force for AIDS Drug Assistance Programs, serves about 150,000 patients spread among 50 or so programs, according to the report.


While HIV programs will benefit from a “significant discount” on the AbbVie product—the drug will be priced less than the standard 23% discount typically given to “poor and underserved patient programs”—the news serviced noted that Gilead, which sells rival HCV medicine Sovaldi, “declined to negotiate” with the task force,  according to its associate director.